Axsome Therapeutics, Inc. stock is up 14.02% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 77.78% of the previous 8 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|07 Nov 15:41||15 Dec, 2023||60.00||134|
|08 Nov 17:04||17 Jan, 2025||90.00||119|
|10 Nov 20:52||10 Nov, 2023||62.00||150|
|13 Nov 17:01||17 Jan, 2025||80.00||6|
|21 Nov 14:54||17 Jan, 2025||80.00||64|
|22 Nov 20:58||17 Jan, 2025||80.00||136|
|27 Nov 18:48||17 Jan, 2025||80.00||229|
|28 Nov 14:53||17 Jan, 2025||60.00||43|
|06 Dec 16:05||19 Jan, 2024||50.00||718|
|07 Dec 16:36||15 Mar, 2024||75.00||208|
Axsome Therapeutics, Inc. engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the. treatment of smoking cessation. The firm was incorporated in 2012 and is based in New York, New York.